Financial Review: Universe Pharmaceuticals (NYSE:UPC) versus Bolt Biotherapeutics (NASDAQ:BOLT)

Universe Pharmaceuticals (NYSE:UPC) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Institutional and Insider Ownership

0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Comparatively, 28.4% of Bolt Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Universe Pharmaceuticals and Bolt Biotherapeutics’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$32.31 million	0.24	-$6.16 million	N/A	N/A
Bolt Biotherapeutics	$7.88 million	5.32	-$69.20 million	($1.83)	-0.60

Universe Pharmaceuticals has higher revenue and earnings than Bolt Biotherapeutics.

Volatility & Risk

Universe Pharmaceuticals has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.

Profitability

This table compares Universe Pharmaceuticals and Bolt Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
Bolt Biotherapeutics	-878.58%	-51.18%	-37.81%

Analyst Recommendations

This is a breakdown of current ratings for Universe Pharmaceuticals and Bolt Biotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	0	0	0	0	N/A
Bolt Biotherapeutics	0	0	2	0	3.00

Bolt Biotherapeutics has a consensus target price of $7.00, indicating a potential upside of 536.36%. Given Bolt Biotherapeutics’ higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Universe Pharmaceuticals.

Summary

Universe Pharmaceuticals beats Bolt Biotherapeutics on 7 of the 11 factors compared between the two stocks.

About Universe Pharmaceuticals

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.